ARVO Annual Meeting
May 3-7, 2026
Denver, USA
https://www.arvo.org/annual-meeting
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Downloads
Upcoming
Events
BIO International Convention
June 22-25, 2026
San Diego, USA
https://convention.bio.org/
CRS (Controlled Release Society) Annual Meeting
July 6-9, 2026
Lisbon, Portugal
https://www.controlledreleasesociety.org/events/crs-2026-annual-meeting-exposition
CPHI South East Asia
July 8-10, 2026
Bangkok, Thailand
https://www.cphi.com/sea/en/attend/attend/why-attend.html
CPHI Milan
October 6-8, 2026
Milan, Italy
https://www.cphi.com/europe/en/exhibit/book-your-stand-milan.html
PODD – Partnership Opportunities in Drug Delivery
October 29-30, 2026
Boston, USA
https://poddconference.com/
BIO-Europe
November 9-11, 2026
Cologne, Germany
https://informaconnect.com/bioeurope/
Past
Events
Archive
AT Uro Congress
May 22-24, 2025
Vienna, Austria
International Partnering in Life-Sciences Society (IPLS)
September 29 – October 1, 2025
Berlin, Germany
https://ipls.online/events/
CPHI Frankfurt
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
PharmaSynergyRx
February 5-6, 2026
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2026/
EuroPLX
March 2-3, 2026
Lisbon, Portugal
https://www.raucon.com/euro-plx/euro-p-l-x-90
BIO-Europe Spring
March 23-25, 2026
Lisbon, Portugal
https://informaconnect.com/bioeurope-spring/
DCAT Week
March 23-26, 2026
New York City, USA
https://dcatweek.org/
PBP World Meeting
March 23-26, 2026
Prague, Czech Republic
https://worldmeeting.org/
analytica
March 24-27, 2026
Munich, Germany
https://analytica.de/de/muenchen/
Latest
News
AMW Strengthens Management Team to Support the Company’s Growth Strategy
AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.
read moreFurther marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America
AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central America. AMW’s goserelin implant is the only approved generic implant version to date for AstraZeneca’s originator product Zoladex®1. Goserelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate or breast cancer, as well as certain gynecological diseases. AMW’s goserelin implant is now available to patients in approximately 30 countries worldwide as a cost-effective alternative therapy.
read moreAMW and AdhexPharma announce strategic partnership for transdermal delivery systems
Today a strategic partnership between AMW GmbH and AdhexPharma SAS on AMW’s transdermal delivery systems technology platform and product portfolio was announced, combining the strengths of both companies in the field of TDS. Under the partnership, AMW will focus on development, marketing authorization and licensing of novel transdermal delivery systems. AdhexPharma will focus on the commercial manufacturing and lifecycle management of the products. AdhexPharma will take over the manufacturing equipment and the IP for AMW’s products Buprenorphine and Rivastigmine and following a transition phase of up to 30 months the contract manufacturing of these Products from AMW.
read moreAMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel
AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, announced today that license and supply agreements (LSAs) have been signed with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel.
read moreAMW signs License and Supply Agreement for Commercialization of Goserelin Implant in a LATAM Country
AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announces that it has entered into a license and supply agreement (LSA) with an undisclosed partner for the commercialization of its goserelin implant in a relevant LATAM country. AMW’s new LATAM partner is active and highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients.
read more